Latest Articles
Quanta Therapeutics Presents Positive Phase 1 Data for QTX3034, an Oral G12D-Preferring Multi-KRAS Inhibitor, in Patients with Advanced Solid Tumors - The Manila Times
Quanta Therapeutics Presents Positive Phase 1 Data for QTX3034, an Oral G12D-Preferring Multi-KRAS Inhibitor, in Patients with Advanced Solid Tumors The Manila Times
Published: Oct. 24, 2025, 3:57 p.m.
FDA Approves Novel Treatment for KRAS-Mutated Ovarian Cancer - Medscape
FDA Approves Novel Treatment for KRAS-Mutated Ovarian Cancer Medscape
Published: May 8, 2025, 8:03 p.m.
Link copied to clipboard!